BioCardia, Inc. (BCDA) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-22

Key Insights

CEO Peter Altman acquired 1,000 shares of BCDA stock across two trading days (April 20-21, 2026) at approximately $1.23 per share, totaling roughly $1,230 in purchases, suggesting confidence in the company's near-term direction.
The transactions were executed through multiple trades at slightly varying prices ($1.21-$1.27 range), indicating active market participation rather than a single block purchase, typical of deliberate accumulation strategies.
Altman's beneficial ownership increased from approximately 274,766 to 275,766 shares following these purchases, demonstrating incremental but consistent insider investment in the company.

Want the newest filings?

This analysis covers the filing from 2026-04-22. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-03-26

The reporting person, Peter Altman, who is the President and CEO of BioCardia, Inc. (BCDA), has purchased 600 shares of the company's common stock on March 24, 2026 at a weighted average price of $1.24 per share, and an additional 300 shares on March 25, 2026 at a weighted average price of $1.22 per share.
The insider buying activity suggests that the CEO has confidence in the company's prospects and is willing to invest their own capital in the stock.
The relatively small size of the transactions, totaling 900 shares, indicates that the insider's buying is likely for personal investment purposes rather than a significant strategic move.

Filed: 2026-02-04

Peter Altman, the President and CEO of BioCardia, Inc. (BCDA), has acquired 5,000 shares of the company's common stock at $1.13 per share, increasing his direct beneficial ownership to 273,866 shares.
This insider buying activity suggests that Altman has confidence in the company's future prospects and is willing to invest his own capital in the stock.
Insider buying can be a positive signal for investors, as it may indicate that management believes the stock is undervalued and has growth potential.

Filed: 2026-01-21

Insider Peter Altman, the President and CEO of BioCardia, Inc., has acquired 600 shares of common stock at $1.32 per share and an additional 300 shares at $1.34 per share, indicating his confidence in the company's prospects.
The transactions occurred within a short timeframe, suggesting Altman's belief that the stock is currently undervalued and presents a favorable investment opportunity.
Insider ownership is an important signal for investors, as it aligns the interests of management with those of shareholders and can indicate positive future prospects for the company.

Other reports for BioCardia, Inc.

Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.